PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

From Oncology Today with Dr Neil Love Dr. Neil Love

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.

CME information and select publications here.

Community discussion

Join the conversation

PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

You May Also Like

Breaking Down: Collapse

Science Friday

Farm Small Farm Smart Daily

The Best of Coast to Coast AM

Eye On The Sky

Radiowissen

New Books in Law

New Books in Public Policy

New Books in Sociology

New Books in Environmental Studies